Clinical trials: Disease, Chronic
Hepatitis C Virus Infection
Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of the treatment with sofosbuvir velpatasvir (SOF/VEL) fixed-dose combination (FDC) with ribavirin (RBV) for 12 weeks in participants…
- Trial name
- NCT02994056
- Testing
- SOF/VEL, RBV
- Where
- 12 sites in United States, France
- Volunteers
- 32 people
- Sponsor
- Gilead Sciences
Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency
Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency
This is a 2-year open-label, multicenter extension of the double-blind, placebo-controlled GTi1201 study. The purpose of this study is to obtain an additional 2 years of safety data for intravenously administered Alpha1-MP 60…
- Trial name
- SPARTA-OLE (NCT02796937)
- Testing
- Alpha-1 MP
- Where
- 28 sites in United States, Australia and 10 more
- Volunteers
- 290 people
- Sponsor
- Grifols Therapeutics LLC
COPD, Pulmonary Hypertension
An Open-Label Study to Evaluate the Safety and Efficacy of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease
A 3-month open label study to evaluate the safety and efficacy of PRX-08066 in patients with pulmonary hypertension and COPD.
- Trial name
- NCT00677872
- Testing
- PRX-08066
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Epix Pharmaceuticals, Inc.
Pulmonary Disease, Chronic Obstructive
Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects
GSK2269557 is being developed as an anti-inflammatory and anti-infective agent for the treatment of inflammatory airways diseases.
- Trial name
- NCT03189589
- Testing
- GSK2269557 500 µg, GSK2269557 750 µg
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Heart Failure
Optimization of the Ambulatory Monitoring for Patients With Heart Failure by Tele-cardiology
Targeted population: Patients with heart failure causing hospitalization during the last twelve months. Hypothesis: The number of all cause deaths and hospitalizations will be smaller for the Telecardiology group than for the…
- Trial name
- OSICAT (NCT02068118)
- Testing
- Telecardiology program
- Where
- 38 sites in France, Martinique
- Volunteers
- 990 people
- Sponsor
- CDM e-Health
Inflammation, Interleukin-1beta
Effect on Cytokines IL-1ß, TNF-α, IL-4, and Total Bacterial Load of a Composition Comprising Olive Oil, Trimethylglycine and Xylitol Delivered as a Toothpaste
The goal of this clinical trial is to learn if a novel composition comprising olive oil, trimethylglycine and xylitol, affects salivary levels of IL-1ß, TNF-α and IL-4 in a group of periodontally healthy, normal and…
- Conditions
- Inflammation, Interleukin-1beta, TNF-α, Cytokine Levels
- Trial name
- NCT06786910
- Testing
- Toothpaste with olive oil, trimethylglycine and xylitol, Toothpaste without olive oil, trimethylglycine nor xylitol
- Where
- Spain
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Mucosa Innovations, S.L.
Chronic Lymphocytic Leukemia
A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
This was an open-label, non-randomized, multicenter, Phase 2 study evaluating the efficacy and safety of ABT-199 in 127 participants with relapsed or refractory chronic lymphocytic leukemia (CLL) after B-cell receptor signaling…
- Trial name
- NCT02141282
- Testing
- Venetoclax
- Where
- 15 sites in United States
- Volunteers
- 127 people
- Sponsor
- AbbVie
Long COVID
Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC)
The primary objective of this study is to evaluate the safety and efficacy of Xiflam versus Placebo in patients who present with signs and symptoms of Long COVID.
- Trial name
- NCT06437223
- Testing
- Tonabersat
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Inflammx Therapeutics Inc
Hepatitis B, Chronic
Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B
Compare the safety of four oral doses of pradefovir after 48 weeks of treatment Select the dose of pradefovir for Phase 3 studies
- Trial name
- NCT00230503
- Testing
- pradefovir mesylate, adefovir dipivoxyl
- Volunteers
- 220 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Graft-versus-host-disease
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
This study will be conducted to compare Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy.
- Trial name
- NCT06821542
- Testing
- INCA034176, Best Available Therapy (BAT)
- Where
- 130 sites in Austria, Belgium and 14 more
- Volunteers
- 9 people
- Sponsor
- Incyte Corporation
B-lymphoid Malignancies, Chronic Lymphocytic Leukemia
Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies
The purpose of this study is to assess the safety and tolerability of escalating doses of SNS-032, given in 3 weekly administrations per cycle and to identify a recommended Phase 2 dose.
- Conditions
- B-lymphoid Malignancies, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Multiple Myeloma
- Trial name
- NCT00446342
- Testing
- SNS-032 Injection
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Sunesis Pharmaceuticals
Hepatitis C Virus Infection
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) in treating hepatitis C virus (HCV) infection in pediatric participants who are undergoing cancer…
- Trial name
- NCT02868242
- Testing
- LDV/SOF
- Where
- Egypt
- Volunteers
- 19 people
- Sponsor
- Gilead Sciences
Chronic Spontaneous Urticaria (CSU)
Efficacy of Bilastine Up-dosing (40 mg ) Versus Combination of Bilastine (20 mg )With Levocitirizine (5 mg) in the Treatment of Chronic Spontaneous Urticaria
This study aims to compare the effectiveness and safety of two commonly used antihistamines, bilastine 20 mg and levocetirizine 5 mg, in patients diagnosed with chronic urticaria.
- Trial name
- NCT07365683
- Testing
- tab bilastine 20 mg, tab bilastine 20 mg + tab levocetrizine 5 mg
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Derma Techno Pakistan
Chronic Low Back Pain (CLBP), Intervertebral Disc Displacement
Sustained Acoustic Medicine for Chronic Low Back Pain Secondary to Herniated Nucleus Pulposus or Other Conditions
ZetrOZ's Ultrasonic Diathermy device is intended for use as a portable and wearable medical device which, when applied to various areas of the body applies Low Intensity Therapeutic Ultrasound (LITUS) to deep tissues.
- Trial name
- NCT02609854
- Testing
- Sustained Acoustic Medicine (SAM)
- Where
- 3 sites in United States
- Volunteers
- 65 people
- Sponsor
- ZetrOZ, Inc.
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
This is a prospective, open-label, multicenter Phase 3 study evaluating the performance of the Albuterol Spiromax dose counter in patients with a diagnosis of asthma and/or COPD.
- Trial name
- NCT01857323
- Testing
- Albuterol Spiromax®
- Where
- 30 sites in United States
- Volunteers
- 317 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma, Chronic Obstructive Pulmonary Disease
Study to Assess the Safety and Efficacy of SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and in Subjects With Chronic Obstructive Pulmonary Disease (Part 2)
This study has two parts. The main purpose of Part 1 of this study will be to examine how safe and effective two doses of SelK2 is on participants with mild asthma.
- Trial name
- NCT04540042
- Testing
- SelK2 (Part 1), SelK2 (Part 2)
- Where
- 2 sites in United Kingdom
- Volunteers
- 61 people
- Sponsor
- Tetherex Pharmaceuticals Corporation
Osteo Arthritis Knee
A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee
The purpose of this study is to evaluate the analgesic efficacy of V120083 twice daily compared to placebo in subjects with moderate to severe chronic pain due to OA of the knee.
- Trial name
- NCT03028870
- Testing
- V120083, Naproxen
- Where
- 30 sites in United States
- Volunteers
- 291 people
- Sponsor
- Purdue Pharma LP
Hepatitis C, Chronic, Hepacivirus
Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED)
In February 2002, a French Consensus Conference on the management of patients with chronic hepatitis C in France was organized. The jury issued several recommendations on pegylated alpha interferon/ribavirin treatment strategy.
- Trial name
- ADEQUATION (NCT00705666)
- Testing
- Peginterferon alfa-2b (SCH 54031), Ribavirin (SCH 18908)
- Volunteers
- 789 people
- Sponsor
- Merck Sharp & Dohme LLC
Renal Impairment
Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis
The primary objective was to evaluate the incidence of clinically significant hypocalcemia following multiple 120 mg subcutaneous doses of denosumab in patients with severe chronic kidney disease (CKD) and CKD on dialysis
- Trial name
- NCT01464931
- Testing
- Denosumab
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Amgen
Hepatitis B Virus
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
At least 1 dose of pegIFNλ will be identified which is safe, well tolerated, and efficacious for the treatment of chronic hepatitis B virus infection (CHB) Amendment 7, Part B Sub Study: The primary purpose of this amendment is…
- Trial name
- LIRA-B (NCT01204762)
- Testing
- pegIFN, pegIFNα-2a, PegIFN lambda
- Where
- 53 sites in United States, Australia and 9 more
- Volunteers
- 197 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.